Skip Navigation

Prostate Cancer

Publications: Prostate Cancer Center of Excellence

The Prostate Cancer Center of Excellence, though its members in basic and clinical programs, includes numerous publications. Some recent examples include:

Han Y, Signorello LB, Strom SS, Kittles RA, Rybicki BA, Stanford JL, Goodman PJ, Berndt SI, Carpten J, Casey G, Chu L, Conti DV, Rand KA, Diver WR, Hennis AJ, John EM, Kibel AS, Klein EA, Kolb S, Le Marchand L, Leske MC, Murphy AB, Neslund-Dudas C. Generalizability of established prostate cancer risk variants in men of African ancestry. Int J Cancer. 2015;136(5):1210-1217.


Gmeiner WH, Boyacioglu O, Stuart CH, Jennings-Gee J, Balaji KC. The cytotoxic and pro-apoptotic activities of the novel fluoropyrimidine F10 towards prostate cancer cells are enhanced by Zn(2+) -chelation and inhibiting the serine protease Omi/HtrA2. Prostate. 2015;75(4):360-369.


Fang X, Gyabaah K, Nickkholgh B, Cline JM, Balaji KC.. Novel in vivo model for combinatorial fluorescence labeling in mouse prostate. Prostate. 2015;():.


Hassan S, Karpova Y, Flores A, D'Agostino R Jr, Danhauer SC, Hemal A, Kulik G. A pilot study of blood epinephrine levels and CREB phosphorylation in men undergoing prostate biopsies. Int Urol Nephrol. 2014;46(3):505-510.


Karlsson R, Aly M, Clements M, Zheng L, Adolfsson J, Xu J, Gronberg H, Wiklund F. A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk. Eur Urol. 2014;65(1):169-176.


Suburu J, Lim K, Calviello G, Chen YQ. RE: serum phospholipid fatty acids and prostate cancer risk in the SELECT trial [letter]. J Natl Cancer Inst. 2014;106(4):dju023.


Kulik G. Personalized prostate cancer therapy based on systems analysis of the apoptosis regulatory network. Asian J Androl. 2014;():.


Lange EM, Johnson AM, Wang Y, Zuhlke KA, Lu Y, Ribado JV, Keele GR, Li J, Duan Q, Li G, Gao Z, Li Y, Xu J, Isaacs WB, Zheng S, Cooney KA. Genome-wide association scan for variants associated with early-onset prostate cancer. PLoS One. 2014;9(4):e93436.


Na R, Ye D, Liu F, Chen H, Qi J, Wu Y, Zhang G, Wang M, Wang W, Sun J, Yu G, Zhu Y, Ren S, Zheng SL, Jiang H, Sun Y, Ding Q, Xu J. Performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and the prostate health index (PHI) in a Chinese hospital-based biopsy population. Prostate. 2014;74(15):1569-1575.


Amin Al Olama A, Kote-Jarai Z, Schumacher FR, Wiklund F, Berndt SI, Benlloch S, Giles GG, Severi G, Neal DE, Hamdy FC, Donovan JL, Hunter DJ, Henderson BE, Thun MJ, Gaziano M, Giovannucci EL, Siddiq A, Travis RC,. A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Hum Mol Genet. 2013;22(2):408-415.


Wicks EE, Fang XL, Balaji KC. Prorainbow: a novel in vivo prostate mouse model to track the origin of prostate cancer [abstract]. Tissue Eng Part A. 2014;20(Suppl 1):S139-S140.


Urbanic JJ, Case D, Lesser G, Enevold G, Naughton M, Danhauer S, Rapp S, Vitolins M, Johnson S, McCollough M, Duncan D, Papagikos M, Shaw EG. L-arginine - based nutritional supplement did not improve erectile function or quality of life in prostate cancer survivors previously treated with radiation therapy: results of CCOP research base protocol 98110-A randomized phase 2 dose. Int J Radiat Oncol Biol Phys. 2014;90(Suppl 1):S86-S87.


Weaver KE, Aziz NM, Arora NK, Forsythe LP, Hamilton AS, Oakley-Girvan I, Keel G, Bellizzi KM, Rowland JH. Follow-up care experiences and perceived quality of care among long-term survivors of breast, prostate, colorectal, and gynecologic cancers. J Oncol Pract. 2014;10(4):e231-e239.


Fang X, Sittadjody S, Gyabaah K, Opara EC, Balaji KC. Novel 3D co-culture model for epithelial-stromal cells interaction in prostate cancer. PLoS One. 2013;8(9):e75187.


Fang XL, Sivanandane S, Gyabaah K Balaji KC. Novel 3D co-cultural model for epithelial-stromal cells interaction in prostate cancer [abstract]. Cancer Res. 2013;73(8 Suppl 1):A4078.


Ayala-Peacock DN, Onyeuku N, Thomas AJ, Garg P, Blackstock AW. A pilot 11C-choline PET/CT imaging study investigating the ability to detect occult metastatic osseous disease in newly diagnosed high-risk prostate adenocarcinoma. Pract Radiat Oncol. 2013;3(2 Suppl 1):S27.


Gu Z, Suburu J, Chen H, Chen YQ. Mechanisms of omega-3 polyunsaturated fatty acids in prostate cancer prevention. Biomed Res Int. 2013;2013():824563.


Palmer NR, Tooze JA, Turner AR, Xu J, Avis NE. African American prostate cancer survivors' treatment decision-making and quality of life. Patient Educ Couns. 2013;90(1):61-68.


Conley-LaComb MK, Saliganan A, Kandagatla P, Chen YQ, Cher ML, Chinni SR. PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling. Mol Cancer. 2013;12():85.


Weaver KE, Foraker RE, Alfano CM, Rowland JH, Arora NK, Bellizzi KM, Hamilton AS, Oakley-Girvan I, Keel G, Aziz NM. Cardiovascular risk factors among long-term survivors of breast, prostate, colorectal, and gynecologic cancers: a gap in survivorship care?. J Cancer Surviv. 2013;7(2):253-261.


Gu Z, Wu J, Wang S, Suburu J, Chen H, Thomas MJ, Shi L, Edwards IJ, Berquin IM, Chen YQ. Polyunsaturated fatty acids affect the localization and signaling of PIP3/AKT in prostate cancer cells. Carcinogenesis. 2013;34(9):1968-1975.


Vitolins MZ, Griffin L, Tomlinson WV, Vuky J, Adams PT, Moose D, Frizzell B, Lesser GJ, Naughton M, Radford JE Jr, Shaw EG. Randomized trial to assess the impact of venlafaxine and soy protein on hot flashes and quality of life in men with prostate cancer. J Clin Oncol. 2013;31(32):4092-4098.


Conley-Lacomb K, Saliganan A, Chen YQ, Kim HRC, Cher ML, Chinni S. PTEN loss mediated Akt activation promotes prostate tumor growth via CXCL12/CXCR4 signaling [abstract]. Cancer Res. 2013;73(8 Suppl 1):A4088.


Hassan S, Karpova Y, Baiz D, Yancey D, Pullikuth A, Flores A, Register T, Cline JM, D'Agostino R Jr, Danial N, Datta SR, Kulik G. Behavioral stress accelerates prostate cancer development in mice. J Clin Invest. 2013;123(2):874-886.


Krishnan B, Smith TL, Dubey P, Zapadka ME, Torti FM, Willingham MC, Tallant EA, Gallagher PE. Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces osteoclastogenesis. Prostate. 2013;73(1):71-82.


Kulik G. Targeting psychoemotional stress to treat prostate cancer. Asian J Androl. 2013;15(3):362-363.


Yancey D, Nelson KC, Baiz D, Hassan S, Flores A, Pullikuth A, Karpova Y, Axanova L, Moore V, Sui G, Kulik G. BAD dephosphorylation and decreased expression of MCL-1 induce rapid apoptosis in prostate cancer cells. PLoS One. 2013;8(9):e74561.


Baiz D, Hassan S, Choi YA, Flores A, Karpova Y, Yancey D, Pullikuth A, Sui G, Sadelain M, Debinski W, Kulik G. Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer. Neoplasia. 2013;15(10):1172-1183.


Hassan S, Karpova Y, Flores A, D'Agostino R Jr, Kulik G. Surgical stress delays prostate involution in mice. PLoS One. 2013;8(11):e78175.


Sun X, Bao J, Nelson KC, Li KC, Kulik G, Zhou X. Systems modeling of anti-apoptotic pathways in prostate cancer: psychological stress triggers a synergism pattern switch in drug combination therapy. PLoS Comput Biol. 2013;9(12):e1003358.


Lin X, Qu L, Chen Z, Xu C, Ye D, Shao Q, Wang X, Qi J, Chen Z, Zhou F, Wang M, Wang Z, He D, Wu D, Gao X, Yuan J, Wang G, Xu Y, Wang G, Dong P, Jiao Y, Yang J, Ou-Yang J, Jiang H,Turner AR, Tao S, Na R, Ding Q, Lu D, Shi R, et al. A novel germline mutation in HOXB13 is associated with prostate cancer risk in Chinese men. Prostate. 2013;73(2):169-175.


Xu J, Lange EM, Lu L, Zheng SL, Wang Z, Thibodeau SN, Cannon-Albright LA, Teerlink CC, Camp NJ, Johnson AM, Zuhlke KA, Stanford JL, Ostrander EA, Wiley KE, Isaacs SD, Walsh PC, Maier C, Luedeke M, Vogel W, Schleutker J,. HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet. 2013;132(1):5-14.


Sun J, Na R, Hsu FC, Zheng SL, Wiklund F, Condreay LD, Trent JM, Xu J. Genetic score is an objective and better measurement of inherited risk of prostate cancer than family history [letter]. Eur Urol. 2013;63(3):585-587.


Sun J, Tao S, Gao Y, Peng T, Tan A, Zhang H, Yang X, Qin X, Hu Y, Feng J, Kim ST, Lin X, Wu Y, Zhang J, Li Z, Li L, Mo L, Liang Z, Shi D, Huang Z, Huang X, Liu M, Liu Q, Zhang S, Lilly Zheng S, Xu J, Mo Z. Genome-wide association study identified novel genetic variant on SLC45A3 gene associated with serum levels prostate-specific antigen (PSA) in a Chinese population. Hum Genet. 2013;132(4):423-429.


 Xu J, Sun J, Zheng SL. Prostate cancer risk-associated genetic markers and their potential clinical utility. Asian J Androl. 2013;15(3):314-322.


Chen Z, Greenwood C, Isaacs WB, Foulkes WD, Sun J, Zheng SL, Condreay LD, Xu J.The G84E mutation of HOXB13 is associated with increased risk for prostate cancer: results from the REDUCE trial. Carcinogenesis. 2013;34(6):1260-1264.


Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S, Dadaev T, Neal DE, Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F,. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet. 2013;45(4):385-391.


Qi J, Tian L, Chen Z, Wang L, Tao S, Gu X, Na R, Jiao Y, Kang J, Zheng S, Xu J, Sun J.Genetic variants in 2q31 and 5p15 are associated with aggressive benign prostatic hyperplasia in a Chinese population. Prostate. 2013;73(11):1182-1190.


Liu W, Xie CC, Thomas CY, Kim ST, Lindberg J, Egevad L, Wang Z, Zhang Z, Sun J, Sun J, Koty PP, Kader AK, Cramer SD, Bova GS, Zheng SL, Gronberg H, Isaacs WB, Xu J. Genetic markers associated with early cancer-specific mortality following prostatectomy. Cancer. 2013;119(13):2405-2412.


Jiang H, Liu F, Wang Z, Na R, Zhang L, Wu Y, Zheng J, Lin X, Jiang D, Sun J, Zheng SL, Ding Q, Xu J. Prediction of prostate cancer from prostate biopsy in Chinese men using a genetic score derived from 24 prostate cancer risk-associated SNPs. Prostate. 2013;73(15):1651-1659.


Na R, Liu F, Zhang P, Ye D, Xu C, Shao Q, Qi J, Wang X, Chen Z, Wang M, He D, Wang Z, Zhou F, Yuan J, Gao X, Wei Q, Yang J, Jiao Y, Ou-Yang J, Zhu Y, Wu Q, Chen H, Lu D, Shi R, Lin X, Jiang H, Wang Z, Jiang D, Sun J,. Evaluation of reported prostate cancer risk-associated SNPs from genome-wide association studies of various racial populations in Chinese men. Prostate. 2013;73(15):1623-1635.


Ren S, Xu J, Zhou T, Jiang H, Chen H, Liu F, Na R, Zhang L, Wu Y, Sun J, Yang B, Gao X, Zheng SL, Xu C, Ding Q, Sun Y. Plateau effect of prostate cancer risk-associated SNPs in discriminating prostate biopsy outcomes. Prostate. 2013;73(16):1824-1835.


    Last Updated: 07-19-2016
    Wake Forest Baptist Ranked among Nation’s ‘Best Hospitals’  25 Years in a Row by U.S. News & World ReportComprehensive Cancer Centers National Designation is Renewed2017-2018 Best DoctorsNursing Magnet StatusJoint Commission Report

    Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.

    © Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157. All Rights Reserved.